[A20-37] Cobicistat (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2020
Commission awarded on 02.04.2020 by the Federal Joint Committee (G-BA).
Immune system and infections
HIV-1 infected adolescents
Added benefit not proven due to lack of suitable study data: single-arm approval study does not provide a comparison with the appropriate comparator therapy.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.